US-based contract research organisation (CRO) Crown Bioscience has extended its partnership with NEXT Oncology.
Through this partnership expansion, the companies will aim to develop clinically relevant cancer organoid and patient-derived xenograft (PDX) models.
The extension will also reaffirm Crown Bioscience's exclusive rights to provide services based on patient samples sourced from NEXT Oncology's global clinical trial network.
By combining Crown Bioscience's expertise in the development of new patient models for oncology with NEXT Oncology's work in the Phase I clinical trial space, the two hope to broaden their portfolio.
This move will also strengthen Crown Bioscience's position as a key player in the translational oncology platform space.
"Recognised for its pioneering work in Phase I clinical oncology trials, we are thrilled to continue our exclusive partnership with NEXT Oncology," stated John Gu, CEO of Crown Bioscience.
"By extending this partnership, we will broaden our portfolio and strengthen our position as a leader in translational oncology platforms and integrated solutions."
"Our combined expertise and global reach will ensure our biopharma partners have rapid and scalable access to unique cancer models."
“Via our efforts to develop new and highly relevant patiet models, Crown's biopharma partners can advance their translational oncology programmes," added Dr Anthony Tolcher, CEO of NEXT Oncology.
“Our combined efforts continue to support both companies’ missions to help cancer patients receive the most advanced medicines possible.”